survey Parenteral anti-epileptics What is your experience? May July 2015

Similar documents
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Use of Subcutaneous Levetiracetam at the end of life:

Palliative Care Impact Survey

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

Antiepileptics Audit

Use of Subcutaneous Levetiracetam at the end of life:

Management of Seizures at the End of Life A new way forward?

Antiepileptics Audit

4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE

Use of Subcutaneous Levetiracetam at the end of life:

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

The last days of life in hospital and at home

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

Syringe driver in Palliative Care

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline

What s New 2003? What new treatments? What have you discontinued? More information please!

Isle of Wight Syringe Driver Compatibility Guidelines

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Symptom Management Guidelines for End of Life Care

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

INQUIRY SCHEDULE OF MEDICATIONS: CLAIRE ROBERTS 22 nd October 1996 CR - INQ

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

Seizure Management in End-of-Life Care: Fit for the Future? DR NICKY HARRIS PALLIATIVE CARE PAEDIATRICIAN PHD CANDIDATE, UWE

SYRINGE DRIVER MEDICATIONS

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Drug Prescription and Administration Record

Palliative Care Emergencies. Additional module if needed

BJF Acute Pain Team Formulary Group

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Lieven Lagae Department of Paediatric Neurology Leuven University Leuven, Belgium. Management of acute seizure settings from infancy to adolescence

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Opioid Conversion Ratios - Guide to Practice 2010

Palliative Prescribing - Pain

Specialist Palliative Care Audit and Guidelines Group (SPAGG)

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

Costing statement. Implementing NICE guidance. January NICE clinical guideline 137

Outline. What is a seizure? What is epilepsy? Updates in Seizure Management Terminology, Triage & Treatment

Algorithms for Symptom Management. In End of Life Care

Status Epilepticus: Implications Outside the Neuro-ICU

End of life prescribing guidance

GUIDELINES FOR THE MANAGEMENT OF DELIRIUM IN ADVANCED CANCER

Conversion of IV Midazolam. Unlike nearly all other benzodiazepine conversions, the conversion between intravenous midazolam and lorazepam has been

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Supportive Care. End of Life Phase

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Care of the Dying Management in Severe Renal Failure

Palliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre

Care of the Dying Management in Severe Renal Failure

Refractory Seizures. Dr James Edwards EMCORE May 30th 2014

On completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

Refractory Status Epilepticus in Children: What are the Options?

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

2016 Treatment Algorithm for Generalized Convulsive Status Epilepticus (SE) in adults and children > 40 kg

Chapter 15. Seizures. Learning Objectives. Learning Objectives 9/11/2012

ESETT OUTCOMES. Investigator Kick-off Meeting Robert Silbergleit, MD

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Care of dying adults in the last days of life. Improving care at the very end of life.

ESETT ELIGIBILITY OVERVIEW. James Chamberlain, MD

Disclosures. What is Status Epilepticus? Purpose of Today s Discussion. Nothing to Disclose. How do I recognize Status Epilepticus?

Sedative-Hypnotics. Sedative Agents (General Considerations)

CrackCast Episode 18 Seizures

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Phenobarbital conversion

STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION

BACKGROUND Measuring renal function :

The Quebec Palliative Sedation Guidelines. Rose DeAngelis, N, MSc(A), CHPCN (C)

Seizures Emergency Treatment

A dog on valium and phenobarbital

Updated advice for nurses who care for patients with epilepsy

Complex Care Hub Manual: Caring for a Child with Epilepsy/Seizures

I Wanna Be Sedated: Palliative Sedation March 30, 2017 Emily L. Riegel, MD

Status Epilepticus And Prolonged Seizures: Guideline For Management In Adults. Contents

Care in the Last Days of Life

Renal Palliative Care Last Days of Life

Management of Complex Febrile Seizures

Calculation of Medications for Special Populations Based on Body Weight and Patient Age

Librium to ativan conversion

Syringe Drivers. Back to top

Palliative care for heart failure patients. Susan Addie

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Goals for sedation during mechanical ventilation

Guideline of status epilepticus management 2017

Document Details Guidance For The Use Of Emergency Rescue Medication for Children With Epilepsy (Administration Of Buccolam)

Ventilation/End of Life Neuromuscular Disorders. Dr Emma Husbands Consultant Palliative Medicine

Chapter 4 Central Nervous System Answers. 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia?

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Management of Severe Agitation

Symptom Management Challenges at End-of-Life

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

CHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island

Transcription:

Parenteral anti-epileptics What is your experience? May July 2015 Number of responses = 99 1a) In patients with pre-existing epilepsy controlled by PO medication that are imminently dying (prognosis <1 week), and are no longer able to take PO tablets, what is generally your first-line course of action? Stop all anti-epileptics, prescribe only p.r.n. benzodiazepine (buccal or SC midazolam or PR diazepam) 18 18% Start parenteral midazolam 68 69% Start parenteral levetiracetam 4 4% Start parenteral phenobarbital 3 3% Start parenteral valproate 1 1% Other (please supply information in question 1b below) 5 5% 1b) Enter further details for 'other' from question 1a. Clonazepam (3 responses 1 reported buccal use) The majority of the further comments reported that their choice would depend on a combination of factors such as previous fitting control, whether there was a parenteral version of the PO drug the patient was taking, other symptoms (including degree of acceptable sedation) and the situation (i.e. hospice, community, hospital) 1c) Please indicate if there is any specific reason for your choice, e.g. availability, cost, familiarity, sedative effects. A summary of the responses received for each of the drug choices: p.r.n. benzodiazepine Availability (1 response) Parenteral midazolam Familiarity (42 responses), availability (21 responses), effective (9 responses), useful for additional symptoms associated with end of life care (7 responses), compatibility information known with other CSCI drugs (4 responses), and low cost (4 responses) Parenteral levetiracetam Lack of sedative effect (1 response), convert directly from PO levetiracetam ( 1 response) Parenteral phenobarbital Effective (2 responses) Parenteral valproate Availability (1 response) palliativedrugs.com 2015 Parenteral anti-epileptics 1

2a) In patients with pre-existing epilepsy controlled by PO medication that are not imminently dying (prognosis >1 week), and are no longer able to take PO tablets, what is generally your first-line course of action? Stop all anti-epileptics, prescribe only p.r.n. benzodiazepine (buccal or SC midazolam or PR diazepam) 8 8% Start parenteral midazolam 39 39% Start parenteral levetiracetam 11 11% Start parenteral phenobarbital 6 6% Start parenteral valproate 6 6% Other (please supply information in question 2b below) 25 25% 2b) Enter further details for 'other' from question 2a. Clonazepam (5 responses 2 reported buccal use) May use PR levetiracetam or use prn benzodiazepines (1 response) Parenteral midazolam + p.r.n. phenobarbital (1 response) Valproate suppository (1 response) The majority of the other responses reported that their choice would depend on a combination of factors such as previous fitting control, whether there was a parenteral version of the PO drug the patient was taking, other symptoms (including degree of acceptable sedation) and the situation (i.e. hospice, community, hospital) 2c) Please indicate if there is any specific reason for your choice, e.g. availability, cost, familiarity, sedative effects. A summary of the responses received for each of the drug choices: p.r.n. benzodiazepine For the best clinical outcome, cost and sedative effects ( 1 response) Parenteral midazolam Familiarity was the predominant reason (12 responses), the rest of the responses received (8 responses) gave reasons such as availability, effectiveness, useful for additional symptoms associated with end of life care, compatibility information and low cost Parenteral levetiracetam Lack of sedative effect was the main reason reported for use (4 responses). Comments were received that members are considering/interested in its use Parenteral phenobarbital Effective (2 responses ), familiar (2 responses), not too sedative at therapeutic doses (1 response) Parenteral valproate Lack of sedative effect (1 response) Other Clonazepam is indicated for epilepsy, and is easily accessible palliativedrugs.com 2015 Parenteral anti-epileptics 2

3a) If you use parenteral midazolam as prophylaxis for seizures when patients are unable to take PO medication, what is generally your initial starting dose? 5mg/24h 7 7% 10mg/24h 18 18% 15mg/24h 10 10% 20mg/24h 33 33% 30mg/24h 14 14% 60mg/24h 0 0% Other 4 4% Do not use 7 7% 3b) Do your patients usually experience sedation with this dose? (yes_no) Yes 26 26% 5mg/24h (1 response) 10mg/24h (0 responses) 15mg/24h (4 responses) 20mg/24h (15 responses) 30mg/24h (4 responses) Other (2 responses) No 56 57% 5mg/24h (6 responses) 10mg/24h (17 responses) 15mg/24h (6 responses) 20mg/24h (15 responses) 30mg/24h (9 responses) Other (1 response) 4a) If you use parenteral levetiracetam as prophylaxis for seizures when patients are unable to take PO medication, what is generally your initial starting dose? 250mg b.d SC over 30min 0 0% 500mg b.d. SC over 30min 1 1% 250mg b.d. IV over 15-30min 1 1% 500mg b.d. IV over 15-30min 2 2% 500mg/24h CSCI 2 2% 1000mg/24h CSCI 0 0% CSCI dose based on 1:1 conversion from prior PO levetiracetam dose 11 11% Other (please supply information in question 4b below) 5 5% Do not use 57 58% 4b) Enter further details for 'other' from question 4a. Use 500mg/24h CSCI if not on levetiracetam orally previously, but would use 1:1 conversion if had been taking levetiracetam orally previously (2 responses) Use IV with dose based on 1:1 conversion from prior oral levetiracetam dose (2 responses) Depends on setting. Use parenteral usually IV in hospital Depends on oral dose of levetiracetam and convert to IV if access, or if not consider SC route palliativedrugs.com 2015 Parenteral anti-epileptics 3

5) If you use parenteral phenobarbital as prophylaxis for seizures when patients are unable to take PO medication, what is generally your initial starting dose and route of administration? Of the 21 members who responded that they used phenobarbital, 13 reported using phenobarbital CSCI. Generally, a 100mg stat dose IM was given followed by 200mg/24h CSCI. For the 3 responses reporting that they would only use phenobarbital second-line, the total daily starting dose was higher at 400-800mg/24h. Note: We are currently running a new survey on the administration and dilution of phenobarbital by CSCI. 6a) If you use parenteral valproate as prophylaxis for seizures when patients are unable to take PO medication, what is generally your initial starting dose and route of administration? CSCI dose based on 1:1 conversion from prior PO valproate dose 12 12% Other (please supply information in question 6b below) 2 2% Do not use 52 53% 6b) Enter further details for 'other' from question 6a. 1:1 conversion from PO to IV dose I usually reduce the dose a little to start with CSCI and then increase to the equivalent of oral dose 15mg/kg in 2 doses 12h apart 7a) If you have used levetiracetam by CSCI, what diluent have you generally used? Water for injection 9 9% 0.9% saline 7 7% Other 3 3% No diluent 4 4% 7b) Have you had any issues of infusion site problems e.g. redness, pain, discomfort with CSCI levetiracetam? If yes, please be as specific as possible. Yes infusion site problem (1 response): Once a very obese patient experienced necrosis of fatty tissue with 500mg levetiracetam in 500mLGlucose 5%. This was controllable and we then switched to midazolam. No infusion site problem (13 responses): Water for injection (5 responses) 0.9% saline (7 responses) Additional comments related to the above responses: No - been well tolerated, including in one patient receiving CSCI for one month (Water for injection) No - has been tolerated well in the patients we have used this for. This has been 3 patients over the past 6 months used for between a couple of days to a few weeks (Water for injection) No - used in 2 patients over approx. 6 weeks daily use between them. Diluted as much as possible for McKinley administration in a 50mL syringe - in view of our unfamiliarity with this drug/route (0.9% saline) We usually dilute levetiracetam with 250-500mL (0.9% saline) palliativedrugs.com 2015 Parenteral anti-epileptics 4

8) Further comments. Clonazepam usually works well, usually without undue sedation Phenobarbital always written up as a p.r.n. in all who are on anti-epileptics whether they take oral or not. This is in anticipation of status epileptics which has not responded to first line p.r.n. midazolam Levetiracetam seemed to give good control in the 2-3 patients we have used it on. Looks promising for the future Several members are interested in the use of levetiracetam and valproate CSCI and would like more information/ protocols or guidelines for use. In order to facilitate this, please send any documents you may have to hq@pallliativedrugs.com and we will share them via the website document library. palliativedrugs.com 2015 Parenteral anti-epileptics 5